Search Results - "Shi, Victor C"

Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure by Zile, Michael R., MD, Claggett, Brian L., PhD, Prescott, Margaret F., PhD, McMurray, John J.V., MD, Packer, Milton, MD, Rouleau, Jean L., MD, Swedberg, Karl, MD, Desai, Akshay S., MD, Gong, Jianjian, PhD, Shi, Victor C., MD, Solomon, Scott D., MD

“…Abstract Background Natriuretic peptides (NP) have prognostic value in heart failure (HF), although the clinical importance of changes in NP from baseline is…”
Get full text

Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure by Damman, Kevin, Gori, Mauro, Claggett, Brian, Jhund, Pardeep S., Senni, Michele, Lefkowitz, Martin P., Prescott, Margaret F., Shi, Victor C., Rouleau, Jean L., Swedberg, Karl, Zile, Michael R., Packer, Milton, Desai, Akshay S., Solomon, Scott D., McMurray, John J.V.

“…The purpose of this study was to evaluate the renal effects of sacubitril/valsartan in patients with heart failure and reduced ejection fraction. Renal…”
Get full text

Health-Related Quality of Life Outcomes in PARADIGM-HF by Lewis, Eldrin F, Claggett, Brian L, McMurray, John J V, Packer, Milton, Lefkowitz, Martin P, Rouleau, Jean L, Liu, Jiankang, Shi, Victor C, Zile, Michael R, Desai, Akshay S, Solomon, Scott D, Swedberg, Karl

“…Patients with heart failure and reduced ejection fraction have impaired health-related quality of life (HRQL) with variable responses to therapies that target…”
Get full text

Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial by Seferovic, Jelena P, MD, Claggett, Brian, PhD, Seidelmann, Sara B, MD, Seely, Ellen W, MD, Packer, Milton, MD, Zile, Michael R, MD, Rouleau, Jean L, MD, Swedberg, Karl, MD, Lefkowitz, Martin, MD, Shi, Victor C, MD, Desai, Akshay S, MD, McMurray, John J V, MD, Solomon, Scott D, MD

“…Summary Background Diabetes is an independent risk factor for heart failure progression. Sacubitril/valsartan, a combination angiotensin receptor-neprilysin…”
Get full text

Comparing LCZ696 With Enalapril According to Baseline Risk Using the MAGGIC and EMPHASIS-HF Risk Scores by Simpson, Joanne, MBChB, Jhund, Pardeep S., MBChB, PhD, Silva Cardoso, Jose, PhD, Martinez, Felipe, MD, Mosterd, Arend, MD, Ramires, Felix, MD, Rizkala, Adel R., PharmD, Senni, Michele, MD, Squire, Iain, MD, Gong, Jianjian, PhD, Lefkowitz, Martin P., MD, Shi, Victor C., MD, Desai, Akshay S., MD, Rouleau, Jean L., MD, Swedberg, Karl, MD, Zile, Michael R., MD, McMurray, John J.V., MD, Packer, Milton, MD, Solomon, Scott D., MD

“…Abstract Background Although most patients in the PARADIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity…”
Get full text

Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy by Okumura, Naoki, Jhund, Pardeep S, Gong, Jianjian, Lefkowitz, Martin P, Rizkala, Adel R, Rouleau, Jean L, Shi, Victor C, Swedberg, Karl, Zile, Michael R, Solomon, Scott D, Packer, Milton, McMurray, John J V

“…In the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure), the angiotensin…”
Get full text

Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction by Selvaraj, Senthil, Claggett, Brian L, Packer, Milton, Zannad, Faiez, Anand, Inder S, Pieske, Burkert, Zhao, Ziqiang, Shi, Victor C, Lefkowitz, Martin P, McMurray, John J V, Solomon, Scott D

“…Background Dyslipidemia is common in heart failure with preserved ejection fraction. Sacubitril/valsartan improves glycemic control and augments natriuretic…”
Get full text

Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM‐HF by Mogensen, Ulrik M., Køber, Lars, Jhund, Pardeep S., Desai, Akshay S., Senni, Michele, Kristensen, Søren L., Dukát, Andrej, Chen, Chen‐Huan, Ramires, Felix, Lefkowitz, Martin P., Prescott, Margaret F., Shi, Victor C., Rouleau, Jean L., Solomon, Scott D., Swedberg, Karl, Packer, Milton, McMurray, John J.V.

“…Aims Elevated serum uric acid concentration (SUA) has been associated with an increased risk of cardiovascular disease, but this may be due to unmeasured…”
Get full text

Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF by Ehteshami-Afshar, Solmaz, Mooney, Leanne, Dewan, Pooja, Desai, Akshay S, Lang, Ninian N, Lefkowitz, Martin P, Petrie, Mark C, Rizkala, Adel R, Rouleau, Jean L, Solomon, Scott D, Swedberg, Karl, Shi, Victor C, Zile, Michael R, Packer, Milton, McMurray, John J V, Jhund, Pardeep S, Hawkins, Nathaniel M

“…Background Chronic obstructive pulmonary disease (COPD) is a common comorbidity in heart failure with reduced ejection fraction, associated with undertreatment…”
Get full text

Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF by McMurray, John J.V., Jackson, Alice M., Lam, Carolyn S.P., Redfield, Margaret M., Anand, Inder S., Ge, Junbo, Lefkowitz, Marty P., Maggioni, Aldo P., Martinez, Felipe, Packer, Milton, Pfeffer, Marc A., Pieske, Burkert, Rizkala, Adel R., Sabarwal, Shalini V., Shah, Amil M., Shah, Sanjiv J., Shi, Victor C., van Veldhuisen, Dirk J., Zannad, Faiez, Zile, Michael R., Cikes, Maja, Goncalvesova, Eva, Katova, Tzvetana, Kosztin, Anamaria, Lelonek, Malgorzata, Sweitzer, Nancy, Vardeny, Orly, Claggett, Brian, Jhund, Pardeep S., Solomon, Scott D.

“…BACKGROUND:Unlike heart failure with reduced ejection fraction, there is no approved treatment for heart failure with preserved ejection fraction, the…”
Get full text

Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure by McMurray, John J.V, Packer, Milton, Desai, Akshay S, Gong, Jianjian, Lefkowitz, Martin P, Rizkala, Adel R, Rouleau, Jean L, Shi, Victor C, Solomon, Scott D, Swedberg, Karl, Zile, Michael R

“…The angiotensin receptor–neprilysin inhibitor LCZ696 was compared with the ACE inhibitor enalapril in patients with advanced heart failure. LCZ696 was superior…”
Get full text

Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF by Vaduganathan, Muthiah, Claggett, Brian L., Desai, Akshay S., Anker, Stefan D., Perrone, Sergio V., Janssens, Stefan, Milicic, Davor, Arango, Juan L., Packer, Milton, Shi, Victor C., Lefkowitz, Martin P., McMurray, John J.V., Solomon, Scott D.

“…The period shortly after hospitalization for heart failure (HF) represents a high-risk window for recurrent clinical events, including rehospitalization or…”
Get full text

Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF by Cunningham, Jonathan W., Claggett, Brian L., O’Meara, Eileen, Prescott, Margaret F., Pfeffer, Marc A., Shah, Sanjiv J., Redfield, Margaret M., Zannad, Faiez, Chiang, Lu-May, Rizkala, Adel R., Shi, Victor C., Lefkowitz, Martin P., Rouleau, Jean, McMurray, John J.V., Solomon, Scott D., Zile, Michael R.

“…Myocardial fibrosis may contribute to the pathophysiology of heart failure with preserved ejection fraction. Given the biochemical targets of…”
Get full text

Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF) by McMurray, John J. V., Packer, Milton, Desai, Akshay S., Gong, Jim, Lefkowitz, Martin P., Rizkala, Adel R., Rouleau, Jean, Shi, Victor C., Solomon, Scott D., Swedberg, Karl, Zile, Michael R.

“…Aims Although the focus of therapeutic intervention has been on neurohormonal pathways thought to be harmful in heart failure (HF), such as the…”
Get full text

Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF by Böhm, Michael, Young, Robin, Jhund, Pardeep S, Solomon, Scott D, Gong, Jianjian, Lefkowitz, Martin P, Rizkala, Adel R, Rouleau, Jean L, Shi, Victor C, Swedberg, Karl, Zile, Michael R, Packer, Milton, McMurray, John J V

“…Compared to heart failure patients with higher systolic blood pressure (SBP), those with lower SBP have a worse prognosis. To make matters worse, the latter…”
Get full text

Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction: PARADIGM-HF by Selvaraj, Senthil, Claggett, Brian, Pozzi, Andrea, McMurray, John J.V, Jhund, Pardeep S, Packer, Milton, Desai, Akshay S, Lewis, Eldrin F, Vaduganathan, Muthiah, Lefkowitz, Martin P, Rouleau, Jean L, Shi, Victor C, Zile, Michael R, Swedberg, Karl, Solomon, Scott D

“…BACKGROUND:The contemporary prognostic value of the physical examination— beyond traditional risk factors including natriuretic peptides, risk scores, and…”
Get full text

Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan by Selvaraj, Senthil, Claggett, Brian L., Böhm, Michael, Anker, Stefan D., Vaduganathan, Muthiah, Zannad, Faiez, Pieske, Burkert, Lam, Carolyn S.P., Anand, Inder S., Shi, Victor C., Lefkowitz, Martin P., McMurray, John J.V., Solomon, Scott D.

“…Guidelines recommend targeting systolic blood pressure (SBP) <130 mm Hg in heart failure with preserved ejection fraction (HFpEF) with limited data. This study…”
Get full text

Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF) by Okumura, Naoki, Jhund, Pardeep S, Gong, Jianjian, Lefkowitz, Martin P, Rizkala, Adel R, Rouleau, Jean L, Shi, Victor C, Swedberg, Karl, Zile, Michael R, Solomon, Scott D, Packer, Milton, McMurray, John J.V

“…BACKGROUND—Many episodes of worsening of heart failure (HF) are treated by increasing oral therapy or temporary intravenous treatment in the community or…”
Get full text

Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF by Jhund, Pardeep S, Fu, Michael, Bayram, Edmundo, Chen, Chen-Huan, Negrusz-Kawecka, Marta, Rosenthal, Arvo, Desai, Akshay S, Lefkowitz, Martin P, Rizkala, Adel R, Rouleau, Jean L, Shi, Victor C, Solomon, Scott D, Swedberg, Karl, Zile, Michael R, McMurray, John J V, Packer, Milton

“…The age at which heart failure develops varies widely between countries and drug tolerance and outcomes also vary by age. We have examined the efficacy and…”
Get full text

Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF by Simpson, Joanne, Jhund, Pardeep S, Silva Cardoso, Jose, Martinez, Felipe, Mosterd, Arend, Ramires, Felix, Rizkala, Adel R, Senni, Michele, Squire, Iain, Gong, Jianjian, Lefkowitz, Martin P, Shi, Victor C, Desai, Akshay S, Rouleau, Jean L, Swedberg, Karl, Zile, Michael R, McMurray, John J V, Packer, Milton, Solomon, Scott D

“…Although most patients in the PARADIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure)…”
Get full text